The idea that we distrust trials is an easy excuse for poor recruitment. But the reality is more nuanced. Public opinion often shows that, despite some wariness, most agree clinical trials are important and would consider getting involved. The challenge is telling the right people about the right opportunities. A consumer mindset is therefore key.
We can no longer shrug our shoulders and say “that’s just how it is”. Too many clinical trials fail to recruit to time or target, or to retain patients. The result? Pharma is haemorrhaging money and patients aren’t seeing the benefits they need. More frustratingly, the solution is staring us in the face.
Clinical research is essential in helping us find out if new therapies really do work and if they can make a difference to patients’ lives.
But with over 300,000 trials looking for around 44 million patients, conducting clinical research is becoming increasingly difficult. We know there are patients out there, often searching desperately for new options or alternatives that they haven’t already tried.
Patient centricity is a misused buzzword to signpost all manner of token efforts, but the real winners will be those who embrace it throughout their organisation. Not just because it’s the right thing to do, but because it is the only way to fix a broken model.
That is the clear message from Havas Lynx Group as it marks Clinical Trials Day (May 20th) with the launch of a new white paper designed to provoke conversation and offer potential solutions to a problem that is costing lives and the sector more than $40bn every year.